TREATMENT WITH RUXOLITINIB IN MYELOFIBROSIS AND VERA POLYTETHEMIA: EXPERIENCE IN A COMARCAL HOSPITAL

被引：0
|
作者：
Mas Esteve, E. [1 ]
Claros Barrachina, N. [1 ]
Bernat Pablo, S. [1 ]
Guinot Martinez, M. [1 ]
机构：
[1] Hosp Univ La Plana Vila Real, Villarreal, Spain
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB- 096
引用
收藏
页码：357 / 358
页数：2
相关论文
共 50 条
  • [31] Ruxolitinib for the treatment of patients with polycythemia vera
    Kiladjian, Jean-Jacques
    Winton, Elliott F.
    Talpaz, Moshe
    Verstovsek, Srdan
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (04) : 391 - 401
  • [32] The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis
    Samuelson, Bethany T.
    Vesely, Sara K.
    Chai-Adisaksopha, Chatree
    Scott, Bart L.
    Crowther, Mark
    Garcia, David
    BLOOD COAGULATION & FIBRINOLYSIS, 2016, 27 (06) : 648 - 652
  • [33] The use of ruxolitinib in the treatment of myelofibrosis: A review of clinical practice and response in a single teaching hospital
    Elhag, S.
    Wadelin, F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 127 - 127
  • [34] Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study
    Palandri, F.
    Auteri, G.
    Abruzzese, E.
    Caocci, G.
    Bonifacio, M.
    Mendicino, F.
    Latagliata, R.
    Iurlo, A.
    Branzanti, F.
    Garibaldi, B.
    Trawinska, M. M.
    Cattaneo, D.
    Krampera, M.
    Mulas, O.
    Martino, E. A.
    Cavo, M.
    Vianelli, N.
    Impera, S.
    Efficace, F.
    Heidel, F.
    Breccia, M.
    Elli, E. M.
    Palumbo, G. A.
    ANNALS OF HEMATOLOGY, 2024, 103 (06) : 1931 - 1940
  • [35] Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
    F. Palandri
    G. Auteri
    E. Abruzzese
    G. Caocci
    M. Bonifacio
    F. Mendicino
    R. Latagliata
    A. Iurlo
    F. Branzanti
    B. Garibaldi
    M. M. Trawinska
    D. Cattaneo
    M. Krampera
    O. Mulas
    E. A. Martino
    M. Cavo
    N. Vianelli
    S. Impera
    F. Efficace
    F. Heidel
    M. Breccia
    E. M. Elli
    G. A. Palumbo
    Annals of Hematology, 2024, 103 : 1931 - 1940
  • [36] RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE EXPERIENCE FROM THE EAST OF ENGLAND
    Russell, J.
    Sparksman, D.
    Dicu, A.
    Maw, K.
    Gomez, C.
    Mangi, M.
    Whalley, I.
    Collins, A.
    Sadullah, S.
    HAEMATOLOGICA, 2017, 102 : 818 - 818
  • [37] Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis
    Devos, Timothy
    Selleslag, Dominik
    Granacher, Nikki
    Havelange, Violaine
    Benghiat, Fleur Samantha
    HEMATOLOGY, 2022, 27 (01) : 23 - 31
  • [38] A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
    Ros Wade
    Robert Hodgson
    Mousumi Biswas
    Melissa Harden
    Nerys Woolacott
    PharmacoEconomics, 2017, 35 : 203 - 213
  • [39] Definition and management of ruxolitinib treatment failure in myelofibrosis
    Pardanani, A.
    Tefferi, A.
    BLOOD CANCER JOURNAL, 2014, 4 : e268 - e268
  • [40] Ruxolitinib in the treatment of patients with myelofibrosis - questions and answers
    Warzocha, Krzysztof
    Homenda, Wojciech
    Pluta, Andrzej
    Sacha, Tomasz
    Cioch, Maria
    Dudzinski, Marek
    Krochmalczyk, Dorota
    Gora-Tybor, Joanna
    Seferynska, Ilona
    Joks, Monika
    Sobas, Marta
    ONCOLOGY IN CLINICAL PRACTICE, 2019, 15 (03): : 167 - 179
12345